Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaji Kumar

Showing results (61-70 of 515) with videos related to

Pageof 52
Sort By:
Oncology and Therapy|April 4, 2022
Current Role of Allogeneic Stem Cell Transplantation in Multiple MyelomaJean-Sébastien Claveau, Francis K Buadi, Shaji Kumar
American Journal of Hematology|May 5, 2025
Optimizing Outcomes in Relapsed and Refractory Multiple Myeloma: Personalized Approaches and Adverse Event ManagementEirini Katodritou, Evangelos Terpos, Suzanne Lentzsch, et al.
Hematology/Oncology Clinics of North America|December 29, 2023
Smoldering Multiple Myeloma: Observation Versus Control Versus CureS Vincent Rajkumar, P Leif Bergsagel, Shaji Kumar
Blood Cancer Journal|May 29, 2026
Monoclonal gammopathy of clinical significance: a multisystem reviewManraj Singh Sra, S Vincent Rajkumar, Shaji Kumar
American Journal of Hematology|April 1, 2003
Acquired von Willebrand's syndrome: a single institution experienceShaji Kumar, Rajiv K Pruthi, William L Nichols
Blood Cancer Journal|April 12, 2022
Cutaneous manifestations of monoclonal gammopathyJean-Sebastien Claveau, David A Wetter, Shaji Kumar
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Thalidomid: current role in the treatment of non-plasma cell malignanciesShaji Kumar, Thomas E Witzig, S Vincent Rajkumar
Expert Review of Hematology|January 8, 2014
Initial treatment of transplant-eligible patients in multiple myelomaLaura Rosiñol, Shaji Kumar, Phillipe Moreau, et al.
Leukemia & Lymphoma|May 21, 2009
Activity of bortezomib administered once every 3 weeks for treatment of relapsed multiple myelomaIbrahim Sadek, Angela Dispenzieri, Morie A Gertz, et al.
British Journal of Haematology|September 18, 2009
An unusual neurological complication of light chain amyloidosisIbrahim Sadek, Prashant Kapoor, Morie A Gertz, et al.
Pageof 52

Showing results (61-70 of 515) with videos related to

Sort By:
Pageof 52
Oncology and Therapy|April 4, 2022
Current Role of Allogeneic Stem Cell Transplantation in Multiple MyelomaJean-Sébastien Claveau, Francis K Buadi, Shaji Kumar
American Journal of Hematology|May 5, 2025
Optimizing Outcomes in Relapsed and Refractory Multiple Myeloma: Personalized Approaches and Adverse Event ManagementEirini Katodritou, Evangelos Terpos, Suzanne Lentzsch, et al.
Hematology/Oncology Clinics of North America|December 29, 2023
Smoldering Multiple Myeloma: Observation Versus Control Versus CureS Vincent Rajkumar, P Leif Bergsagel, Shaji Kumar
Blood Cancer Journal|May 29, 2026
Monoclonal gammopathy of clinical significance: a multisystem reviewManraj Singh Sra, S Vincent Rajkumar, Shaji Kumar
American Journal of Hematology|April 1, 2003
Acquired von Willebrand's syndrome: a single institution experienceShaji Kumar, Rajiv K Pruthi, William L Nichols
Blood Cancer Journal|April 12, 2022
Cutaneous manifestations of monoclonal gammopathyJean-Sebastien Claveau, David A Wetter, Shaji Kumar
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Thalidomid: current role in the treatment of non-plasma cell malignanciesShaji Kumar, Thomas E Witzig, S Vincent Rajkumar
Expert Review of Hematology|January 8, 2014
Initial treatment of transplant-eligible patients in multiple myelomaLaura Rosiñol, Shaji Kumar, Phillipe Moreau, et al.
Leukemia & Lymphoma|May 21, 2009
Activity of bortezomib administered once every 3 weeks for treatment of relapsed multiple myelomaIbrahim Sadek, Angela Dispenzieri, Morie A Gertz, et al.
British Journal of Haematology|September 18, 2009
An unusual neurological complication of light chain amyloidosisIbrahim Sadek, Prashant Kapoor, Morie A Gertz, et al.
Pageof 52